Previous 10 | Next 10 |
CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin Expects to initiate Phase 2 trial during the first quarter of 2021 PR Newswire HOUSTON, Nov. 17, 2020 HOUSTON , Nov. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc....
CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4:30 PM ET Today The discussion will be moderated by Robert LeBoyer, Managing Director of Equity Research at Ladenburg Thalmann & Co., Inc. PR Newswire HOUSTON, ...
CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review CNS to Discuss Potentially Pivotal Phase 2 Trial for Berubicin in Webcast on November 12th; Adaptive Trial Design May Open Opportunity for Expedited Pathway fo...
CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial CNS' lead drug candidate Berubicin is proposed for the treatment of glioblastoma multiforme ("GBM"), an aggressive form of brain cancer PR Newswire HOUSTON, Oct. 29, 2020 HO...
CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial PR Newswire HOUSTON, Oct. 20, 2020 HOUSTON , Oct. 20, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical comp...
CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV PR Newswire HOUSTON, Oct. 12, 2020 HOUSTON , Oct. 12, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutica...
CNS Pharmaceuticals (CNSP) European manufacturer, BSP Pharmaceuticals has begun the manufacturing process for Berubicin Drug Product.The drug is a lead candidate for the treatment of glioblastoma multiforme or GBM, an aggressive form of brain cancer currently considered incurable.The company'...
CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe PR Newswire HOUSTON, Oct. 9, 2020 HOUSTON , Oct. 9, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the dev...
CNS Pharmaceuticals Achieves Critical Manufacturing Milestone PR Newswire HOUSTON, Oct. 1, 2020 HOUSTON , Oct. 1, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the devel...
HOUSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today annou...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NASDAQ Market:
CNS Pharmaceuticals Inc. Website:
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held...
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its ab...
New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant t...